Pharmaceutical companies from across the world along with government agencies have partnered to develop a cure for the new coronavirus (Covid-19) that emerged from Wuhan, China.
17 February 2020
7 February 2020
A Phase I clinical trial of monoclonal antibody (mAb) CIS43LS against malaria started the enrolment of healthy adults at the NIH Clinical Center in Bethesda, Maryland, US, and Acceleron Pharma...
3 January 2020
Athersys reports positive data from MultiStem cell therapy trial and CRISPR and Vertex treat first patient in gene-editing therapy trial. Clinicaltrialsarena.com wraps up the key headlines from 2019.
6 December 2019
Eli Lilly and Boehringer Ingelheim started a Phase III clinical trial, EMPULSE, to evaluate whether Jardiance (empagliflozin) improves acute heart failure, and The Janssen Pharmaceutical Companies of Johnson & Johnson...
25 November 2019
Creating electronic versions of documents and processes underlying clinical trials is becoming the norm. Cancer Research UK’s Stephen Nabarro walk us through its implementation of Veeva Vault eTMF two years...
8 November 2019
GSK has initiated the Phase III EAGLE programme of gepotidacin for the treatment of uncomplicated urinary tract infection and urogenital gonorrhoea, and AstraZeneca has reported that a combination of Imfinzi...
5 October 2019
NIH kick starts hunt for neuroprotective stroke treatments and Denali begins dosing Parkinson’s patients in Phase Ib trial. Clinicaltrialsarena.com wraps up the key headlines from September 2019.
5 September 2019
Biopharmaceutical firm Retrophin reported that the Phase III clinical trial of fosmetpantotenate failed to meet endpoints in pantothenate kinase-associated neurodegeneration (PKAN) patients; and MyoKardia has commenced dosing of patients in...
8 July 2019
AstraZeneca’s human monoclonal antibody Imfinzi (durvalumab) improved overall survival in the Phase III CASPIAN trial in first-line extensive-stage small cell lung cancer (SCLC).
18 June 2019
Novartis reported that the first clinical trial in its Phase III PLATINUM programme for QMF149 has met primary and key secondary endpoints in people with inadequately controlled asthma; and The...